NCT02906397View on ClinicalTrials.gov

Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 30, 2017

Primary Completion Date

July 21, 2021

Study Completion Date

July 21, 2021

Conditions
ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
Interventions
DRUG

Galunisertib 150mg by mouth twice a day

on days 1-14 of 28 day cycles

RADIATION

Stereotactic Body Radiotherapy (SBRT)

18GY delivered in one fraction between C1D15 and C1D28

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT02906397 - Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC) | Biotech Hunter | Biotech Hunter